Topic: gastroesophageal reflux disease (GERD)
Pear Therapeutics is expanding its app-based platform to conditions outside of the brain and mental health through a GI-focused deal with Ironwood.
Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.
EndoGastric Solutions continues its fundraising march, gathering another $45 million for its acid reflux device treatment.
With the Shire deal done, Takeda is looking to lighten the load a little from its central R&D base. To that end, it has launched a new biotech, Phathom.
The positive narrative spun by Ironwood’s management failed to convince investors, who seized on perceived underwhelming efficacy data.
Pelvic health player Laborie is boosting its urodynamics stable with an acquisition of Andromeda Medizinische Systems for an undisclosed amount.
Ironwood is already chalking up success with its first colonic delivery drug Linzess, but analysts reckon another payoff could come from two follow-up drugs.
Johnson & Johnson’s Ethicon unit has agreed to acquire Torax Medical, which markets devices for the treatment of gastrointestinal conditions stemming from sphincter issues.